Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Receives $14.60 Consensus PT from Analysts
Black Diamond Therapeutics, Inc. (NASDAQ:BDTX – Get Free Report) has earned a consensus rating of “Buy” from the five brokerages that are currently covering the firm, Marketbeat reports. Five research analysts have rated the stock with a buy recommendation. The average 12-month target price among brokerages that have covered the stock in the last year […]
Black Diamond Therapeutics, Inc. (NASDAQ:BDTX – Get Free Report) has earned a consensus rating of “Buy” from the five brokerages that are currently covering the firm, Marketbeat reports. Five research analysts have rated the stock with a buy recommendation. The average 12-month target price among brokerages that have covered the stock in the last year […]
